256 related articles for article (PubMed ID: 37217970)
1. Efficacy and safety of particle therapy for inoperable stage II-III non-small cell lung cancer: a systematic review and meta-analysis.
Chen Y; Luo H; Liu R; Tan M; Wang Q; Wu X; Du T; Liu Z; Sun S; Zhang Q; Wang X
Radiat Oncol; 2023 May; 18(1):86. PubMed ID: 37217970
[TBL] [Abstract][Full Text] [Related]
2. Clinical results of proton beam radiotherapy for inoperable stage III non-small cell lung cancer: a Japanese national registry study.
Tatebe H; Harada H; Mori K; Iwata H; Akimoto T; Murakami M; Waki T; Ogino T; Nakamura M; Taguchi H; Nakayama H; Satouchi M; Aoyama H
J Radiat Res; 2023 Jun; 64(Supplement_1):i8-i15. PubMed ID: 37137157
[TBL] [Abstract][Full Text] [Related]
3. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study.
Chang JY; Verma V; Li M; Zhang W; Komaki R; Lu C; Allen PK; Liao Z; Welsh J; Lin SH; Gomez D; Jeter M; O'Reilly M; Zhu RX; Zhang X; Li H; Mohan R; Heymach JV; Vaporciyan AA; Hahn S; Cox JD
JAMA Oncol; 2017 Aug; 3(8):e172032. PubMed ID: 28727865
[TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer.
Hayashi K; Yamamoto N; Nakajima M; Nomoto A; Tsuji H; Ogawa K; Kamada T
Cancer Sci; 2019 Feb; 110(2):734-741. PubMed ID: 30467928
[TBL] [Abstract][Full Text] [Related]
5. Proton therapy (PT) combined with concurrent chemotherapy for locally advanced non-small cell lung cancer with negative driver genes.
Jin Y; Shimizu S; Li Y; Yao Y; Liu X; Si H; Sakurai H; Xiao W
Radiat Oncol; 2023 Nov; 18(1):189. PubMed ID: 37974211
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis comparing efficacy and safety between proton beam therapy versus carbon ion radiotherapy.
Jang JY; Kim K; Chen MF; Akimoto T; Wang MLC; Kim MJ; Kim K; Lee TH; Yoo GS; Park HC
Cancer Med; 2024 Feb; 13(3):e7023. PubMed ID: 38396380
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of chemoradiotherapy versus radiation alone in patients with inoperable locally advanced non-small-cell lung cancer: A meta-analysis and systematic review.
Hung MS; Wu YF; Chen YC
Medicine (Baltimore); 2019 Jul; 98(27):e16167. PubMed ID: 31277121
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
10. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
[TBL] [Abstract][Full Text] [Related]
12. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
13. A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC).
Takahashi W; Nakajima M; Yamamoto N; Yamashita H; Nakagawa K; Miyamoto T; Tsuji H; Kamada T; Fujisawa T
Cancer; 2015 Apr; 121(8):1321-7. PubMed ID: 25641119
[TBL] [Abstract][Full Text] [Related]
14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
15. The effect of consolidation chemotherapy after concurrent chemoradiotherapy on the survival of patients with locally advanced non-small cell lung cancer: a meta-analysis.
Wang X; Ding X; Kong D; Zhang L; Guo Y; Ren J; Hu X; Yang J; Gao S
Int J Clin Oncol; 2017 Apr; 22(2):229-236. PubMed ID: 28005209
[TBL] [Abstract][Full Text] [Related]
16. Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy.
Chen J; Lu JJ; Ma N; Zhao J; Chen C; Fan M; Jiang G; Mao J
Radiat Oncol; 2019 Jan; 14(1):16. PubMed ID: 30683133
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
18. Clinical Efficacy and Safety of Proton and Carbon Ion Radiotherapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Li M; Li X; Yao L; Han X; Yan W; Liu Y; Fu Y; Wang Y; Huang M; Zhang Q; Wang X; Yang K
Front Oncol; 2021; 11():709530. PubMed ID: 34712607
[TBL] [Abstract][Full Text] [Related]
19. Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.
Chi A; Chen H; Wen S; Yan H; Liao Z
Radiother Oncol; 2017 Jun; 123(3):346-354. PubMed ID: 28545956
[TBL] [Abstract][Full Text] [Related]
20. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
